Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03340883 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 1 study, sponsored by Chinook Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03340883: Clinical Trial Phase 1 study, sponsored by Chinook Therapeutics.
NCT03340883 is a Phase 1 study that was terminated before completion, run by Chinook Therapeutics. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03340883, a Phase 1 study, was terminated before completion, sponsored by Chinook Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a Phase 1/2 study designed to evaluate the safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma whose disease has progressed after 3 or more prior systemic therapies.
Primary Outcome
Number of patients reporting treatment-related adverse events that qualify as dose-limiting toxicities (DLTs) of BION-1301 as a single agent
Interventions
- BIOLOGICAL BION-1301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2019-07-09 |
| Phase | Phase 1 |
Why NCT03340883 stopped before completion
NCT03340883 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which BION-1301 is the first listed.
NCT03340883 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03340883 about?
NCT03340883 is a clinical study titled "Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)". This is a Phase 1/2 study designed to evaluate the safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma whose disease has progressed after 3 or more prior systemic therapies.
What is the current status of trial NCT03340883?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-11-15. Estimated completion is 2019-07-09.
What interventions are being tested in trial NCT03340883?
The interventions under investigation include: BION-1301 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03340883?
This trial is sponsored by Chinook Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03340883's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI